Abstract:Background: Endocrine therapies are the mainstay of treatment for oestrogen receptor (ER)-positive (ER+) breast cancer (BC). However, resistance remains problematic largely due to enhanced cross-talk between ER and growth factor pathways, circumventing the need for steroid hormones. Previously, we reported the anti-proliferative effect of everolimus (RAD001-mTORC1 inhibitor) with endocrine therapy in resistance models; however, potential routes of escape from treatment via ERBB2/3 signalling were observed. We hypothesised that combined targeting of three cellular nodes (ER, ERBB, and mTORC1) may provide enhanced long-term clinical utility. Methods: A panel of ER+ BC cell lines adapted to long-term oestrogen deprivation (LTED) and expressing ESR1 wt or ESR1 Y537S , modelling acquired resistance to an aromatase-inhibitor (AI), were treated in vitro with a combination of RAD001 and neratinib (pan-ERBB inhibitor) in the presence or absence of oestradiol (E2), tamoxifen (4-OHT), or fulvestrant (ICI182780). End points included proliferation, cell signalling, cell cycle, and effect on ER-mediated transactivation. An in-vivo model of AI resistance was treated with monotherapies and combinations to assess the efficacy in delaying tumour progression. RNA-seq analysis was performed to identify changes in global gene expression as a result of the indicated therapies. Results: Here, we show RAD001 and neratinib (pan-ERBB inhibitor) caused a concentration-dependent decrease in proliferation, irrespective of the ESR1 mutation status. The combination of either agent with endocrine therapy further reduced proliferation but the maximum effect was observed with a triple combination of RAD001, neratinib, and endocrine therapy. In the absence of oestrogen, RAD001 caused a reduction in ER-mediated transcription in the majority of the cell lines, which associated with a decrease in recruitment of ER to an oestrogen-response element on the TFF1 promoter. Contrastingly, neratinib increased both ER-mediated transactivation and ER recruitment, an effect reduced by the addition of RAD001. In-vivo analysis of an LTED model showed the triple combination of RAD001, neratinib, and fulvestrant was most effective at reducing tumour volume. Gene set enrichment analysis revealed that the addition of neratinib negated the epidermal growth factor (EGF)/EGF receptor feedback loops associated with RAD001. Conclusions: Our data support the combination of therapies targeting ERBB2/3 and mTORC1 signalling, together with fulvestrant, in patients who relapse on endocrine therapy and retain a functional ER.

RAD001 Offers a Therapeutic Intervention Through Inhibition of Mtor As a Potential Strategy for Esophageal Cancer.

[RAD001 Reverses Radio-Resistance and Exerts Synergistic Tumor Inhibition with 5-Fluorouracil].

Inhibition of esophageal cancer growth through the suppression of PI3K/AKT/mTOR signaling pathway

Lack of Compensatory Pakt Activation and Eif4e Phosphorylation of Lymphoma Cells Towards Mtor Inhibitor, RAD001

Attenuation of everolimus-induced cytotoxicity by a protective autophagic pathway involving ERK activation in renal cell carcinoma cells

The Combination of RAD001 and MK-2206 Exerts Synergistic Cytotoxic Effects Against PTEN Mutant Gastric Cancer Cells: Involvement of MAPK-dependent Autophagic, but Not Apoptotic Cell Death Pathway.

Combinations of Mtorc1 Inhibitor RAD001 with Gemcitabine and Paclitaxel for Treating Non-Hodgkin Lymphoma.

Combining MTI-31 with RAD001 inhibits tumor growth and invasion of kidney cancer by activating autophagy

Efficacy and Safety of Everolimus Plus Somatostatin Analogues in Patients with Neuroendocrine Tumors

Figure S6 from Targeting AKT with Oridonin Inhibits Growth of Esophageal Squamous Cell Carcinoma <i>in Vitro</i> and Patient-Derived Xenografts <i>in Vivo</i>

First-in-Human Phase 1 Study of ES-072, an Oral Mutant-Selective EGFR T790M Inhibitor, in Non–Small-Cell Lung Cancer

RAD001 (everolimus) enhances TRAIL cytotoxicity in human leukemic Jurkat T cells by upregulating DR5

Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases

Synergistic anticancer effects of everolimus (RAD001) and Rhein on gastric cancer cells via phosphoinositide-3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway

Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer

Rapamycin suppresses the PI3K/AKT/mTOR signaling pathway by targeting SIRT1 in esophageal cancer

Data from AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with <i>In vitro</i> and <i>In vivo</i> Antitumor Activity

Combined Targeting of AKT and Mtor Synergistically Inhibits Proliferation of Hepatocellular Carcinoma Cells.

Azd8055 Is A Potent, Selective, And Orally Bioavailable Atp-Competitive Mammalian Target Of Rapamycin Kinase Inhibitor With In Vitro And In Vivo Antitumor Activity

Therapeutic Implications of Mtor Inhibitors in the Treatment of Gastric Cancer.

Combined Targeting of AKT and Mtor Using MK‐2206 and RAD001 is Synergistic in the Treatment of Cholangiocarcinoma